Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Vigil Neuroscience, Inc.
Vigil Neuroscience, Inc. News
Jul 14, 2025 - businesswire.com
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL
Jun 25, 2025 - zacks.com
Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?
Vigil Neuroscience, Inc. Quantitative Score
About Vigil Neuroscience, Inc.
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Vigil Neuroscience, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Vigil Neuroscience, Inc. Financials
Table Compare
Compare VIGL metrics with: | |||
|---|---|---|---|
Earnings & Growth | VIGL | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | VIGL | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | VIGL | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | VIGL | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Vigil Neuroscience, Inc. Income
Vigil Neuroscience, Inc. Balance Sheet
Vigil Neuroscience, Inc. Cash Flow
Vigil Neuroscience, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Vigil Neuroscience, Inc. Executives
| Name | Role |
|---|---|
| Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. | President, Chief Executive Officer & Director |
| Dr. Petra Kaufmann M.D., M.S. | Chief Medical Officer |
| Ms. Jennifer Ziolkowski CPA | Chief Financial Officer |
| Dr. David Gray Ph.D. | Chief Scientific Officer |
| Ms. Sharon Morani | Senior Director of Facilities & Operations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. | President, Chief Executive Officer & Director | 1967 | 940.7K | |
| Dr. Petra Kaufmann M.D., M.S. | Chief Medical Officer | 1966 | 665.9K | |
| Ms. Jennifer Ziolkowski CPA | Chief Financial Officer | Female | 1975 | 650.89K |
| Dr. David Gray Ph.D. | Chief Scientific Officer | 1975 | 601.57K | |
| Ms. Sharon Morani | Senior Director of Facilities & Operations | Female | -- |
Vigil Neuroscience, Inc. Insider Trades
| Date | 5 Aug |
| Name | Atlas Venture Fund XII, L.P. |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 1027978 |
| Date | 5 Aug |
| Name | Thistle Mary |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 5000 |
| Date | 5 Aug |
| Name | Thistle Mary |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 18068 |
| Date | 5 Aug |
| Name | Thistle Mary |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 12155 |
| Date | 5 Aug |
| Name | Kaufmann Petra |
| Role | Chief Medical Officer |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 144000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 5 Aug | Atlas Venture Fund XII, L.P. | 10 percent owner | Disposed | D-Return | 1027978 |
| 5 Aug | Thistle Mary | Director | Disposed | D-Return | 5000 |
| 5 Aug | Thistle Mary | Director | Disposed | D-Return | 18068 |
| 5 Aug | Thistle Mary | Director | Disposed | D-Return | 12155 |
| 5 Aug | Kaufmann Petra | Chief Medical Officer | Disposed | D-Return | 144000 |